ARCHIVES

LabCorp Marketing Of Ovarian Cancer Test Unlawful, FDA Says In Warning Letter.

This article is from The Cancer Letter archive.

Vol. 34 No. 38 | October 17, 2008

Download PDF Visit The Full Archive

Related Articles

NY Attorney General Sues Drug Companies Over Cancer Drug Pricing Deals

February 14, 2003

NSABP’s Pink Sheet; Fisher’s Control Had A Downside, Review Said

June 24, 1994

FDA Official Outlines agency’s Views On Efficacy Requirement

June 16, 1999

DCCP Board Approves Concept Of NMR Interintuitional Clinical Research

January 27, 1984

In Brief: Adamson’s Appointment Official As DCCP Director; NCI Holds Current Spending To 12 Percent Level

October 23, 1981

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

December 28, 2012